Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
-
Recent Posts
- The Cost of Price: Why and How to Get Beyond Intellectual Property Internalism
- WHA 65 adopted the resolution for way forward on CEWG report on R&D
- Corporations Win Big in Battle Against Investment Regulation
- US and EU Derailing Ten-year Process to Create Health Research & Development Convention
- MSF: Update on debates at World Health Assembly on a possible R&D convention, 23 May 2012
Categories
Tag Archives: Patent
Petition: Join the global campaign against Novartis
Novartis: Take your claws off our medicines ! India is known as the ‘Pharmacy of the developing world’ for producing and supplying affordable generic drugs to more than 150 developing countries in Asia, Africa and Latin America. But India’s capacity … Continue reading
Posted in Generic drug, Indian Patent Law, Novartis Case, Sec 3 (d)
Tagged India, India Supreme Court, Novartis, Patent
Leave a comment
India – prices of patented medicines and compulsory licence test case
UPDATE ON APPLICATION U/S 84 OF THE INDIAN PATENT LAW FOR GENERIC PRODUCTION OF PATENTED CANCER DRUG - SORAFENIB TOSYLATE Background – Changes in price due to the introduction of product patent regime are starting to be experienced in India. This … Continue reading
Posted in Bolar provision, Compulsory Licensing
Tagged Bayer, cancer drug, Natco, Patent, Sorafenib
1 Comment
Press: Natco may seek compulsory licence for Bayer’s cancer drug
Source: Economic Times, 24.1.2011, by Khomba Singh NEW DELHI: Natco Pharma plans to seek a compulsory licence from the government to make Bayer AG’s Nexavar in India, invoking a provision in local laws that allows generic drugmakers to make and … Continue reading
Posted in Compulsory Licensing
Tagged Compulsory license, Generic drug, India, Patent
Leave a comment
IP Watch: Europe’s Outlook For 2011: EU Patent, Digital Content, Innovation And Free Trade
Source: Intellectual Property Watch, 13.01.2011, by Dugie Standeford Excerpt – “New Medical Innovation Models Coming? In November 2010, the European Parliament hosted a discussion on biomedical innovation with a view to formulating EU policies, Knowledge Ecology International, TransAtlantic Consumer Dialogue, … Continue reading
Press: AIDS drug patents by Abbot, BMS rejected
Source: The Time of India, 13.1.2011, by Rupali Mukherjee MUMBAI: There’s encouraging news for AIDS patients as well as generic companies. The Indian Patent Office recently rejected applications related to two key AIDS medicines—lopinavir/ritonavir and atazanavir —as they did not … Continue reading
Posted in HIV/Aids
Tagged Generic drug, HIV/Aids, India, Médecins Sans Frontières, Patent
Leave a comment
Data Exclusivity and India-EU FTA: Interview with D.G. Shah of Indian Pharmaceutical Alliance
Interview with D.G. Shah, Secretary-General of Indian Pharmaceutical Alliance (IPA) New Delhi, 13.01.2011 – This week another round of negotiations between the EU and India on a bilateral free trade and investment agreement (India-EU FTA) is taking place in New … Continue reading
The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation
By Liza Porteus Viana , 11 Jan 2011, Intellectual Property Watch In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how, exactly, to recognise the true value of a firm’s intellectual property, … Continue reading
Press: Patent office rejects Abbott Labs plea for expensive AIDS drug
Source: DNA, 04.01.2011, by Priyanka Golikeri HIV/AIDS patients across the world can rejoice on this: the Mumbai Patent Office has rejected a patent application on a crucial medicine by multinational company Abbott Laboratories. This rejection allows low cost generic versions … Continue reading
Posted in HIV/Aids, Patent Opposition
Tagged Generic drug, HIV/Aids, India, Intellectual property, Patent, Pharmaceutical industry
Leave a comment
Press: Supreme Court rejects Bayer’s appeal for patent linkage in India
Source: Pharmabiz, 01.12.2010 “The Supreme Court has rejected the Special Leave Petition (SLP) filed by multinational drug company Bayer Corporation against the Delhi High Court’s February 9, 2010 decision in which the High Court had rejected Bayer’s petition seeking patent … Continue reading
